MENU
Showcases Stock ranks Forex

Travere Therapeutics Inc (TVTX)
28.63  0.8 (2.87%) 08-08 16:00
Open: 27.67 Pre. Close: 27.83
High: 29.14 Low: 27.22
Volume: 1,457,816 Market Cap: 1,831M
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and patient advocacy organizations, CDG Care, and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 29.157 - 29.244 29.244 - 29.34
Low: 26.969 - 27.07 27.07 - 27.183
Close: 28.445 - 28.603 28.603 - 28.781
Stock Technical Analysis
Overall:     
Target: Six months: 34.04
One year: 39.75
Support: Support1: 24.73
Support2: 22.00
Resistance: Resistance1: 29.14
Resistance2: 34.04
Pivot: 24.48
Moving Averages: MA(5): 25.85
MA(20): 24.48
MA(100): 24.99
MA(250): 25.87
MACD: MACD(12,26): 0.55
Signal(12,26,9): 0.06
%K %D: %K(14,3): 90.19
%D(3): 72.06
RSI: RSI(14): 70.30
52-Week: High: 31.65
Low: 13.7519
Change(%): 60.7
Average Vol(K): 3-Month: 819
10-Days: 1065
Price, MAs and Bollinger Bands
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.

[ TVTX ] has closed It is unclear right now based on current values. 50.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
Stock chart
Stock News
Mon, 08 Aug 2022
Travere Therapeutics, Inc. (NASDAQ:TVTX) Given Consensus Rating of "Buy" by Analysts - MarketBeat

Thu, 04 Aug 2022
Travere: Q2 Earnings Snapshot - The Advocate

Thu, 28 Jul 2022
Travere Therapeutics to Report Second Quarter 2022 Financial Results - GlobeNewswire

Tue, 12 Jul 2022
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Mon, 11 Jul 2022
Hennion & Walsh Asset Management Inc. Purchases 16339 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) - Defense World

Mon, 16 May 2022
Travere Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Sparsentan for the Treatment of IgA Nephropathy - Yahoo Finance

Financial Analysis
Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Exchange:  NASDAQ Global Market
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 63.51
Shares Float (M) 46.22
% Held by Insiders 1.44
% Held by Institutions 112.98
Shares Short (K) 6690
Shares Short Prior Month (K) 6630
Stock Financials
EPS -3.290
Book Value (p.s.) 3.280
Profit Margin -88.46
Operating Margin -68.95
Return on Assets (ttm) -12.4
Return on Equity (ttm) -70.8
Qtrly Rev. Growth 2.3
Gross Profit (p.s.) 3.475
Sales Per Share 3.599
EBITDA (p.s.) -2.046
Qtrly Earnings Growth
Operating Cash Flow (M) -43.64
Levered Free Cash Flow (M) -13.74
Stock Valuation
PE Ratio -8.70
PEG Ratio -0.02
Price to Book value 8.73
Price to Sales 7.95
Price to Cash Flow -41.67
Stock Dividends
Dividend
Dividend Yield
Dividend Growth

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android